Delayed Pressure Urticaria
A physical urticaria where sustained pressure causes delayed (3-12h), painful, deep cutaneous swelling that persists for days.
Emergency Management: Severe acute angioedema involving the airway requires immediate Epinephrine 0.3 mg IM, though pure DPU rarely affects mucosal surfaces.
Delayed pressure urticaria (DPU) is a form of physical urticaria characterized by the development of erythematous, deep swelling, and painful wheals in areas subjected to sustained pressure. Unlike acute urticaria, the lesions typically appear 3 to 12 hours after the pressure stimulus and can persist for 12 to 72 hours. It frequently involves the soles of the feet, palms, buttocks, and areas under tight clothing.
Detailed Overview
DPU is mediated by mast cell degranulation triggered by mechanical stress, though the delayed onset suggests involvement of other inflammatory mediators such as leukotrienes, kinins, and cytokines (e.g., IL-6). The condition significantly impacts the quality of life due to the pain and functional impairment, especially in individuals with physically demanding jobs. It is often refractory to standard antihistamine therapy and frequently requires systemic anti-inflammatory or immunomodulatory treatment.
Epidemiology & Demographics
Accounts for less than 5% of chronic urticaria cases. Peak age of onset is in the 20s to 30s. It affects both genders, though some studies show a slight male predominance. Often coexists with chronic spontaneous urticaria (CSU) in up to 30% of patients.
Etiological Mechanism
The primary etiology is mechanical pressure. The precise mechanism linking physical force to mast cell activation is not fully understood, but it may involve mechanosensitive ion channels or local microvascular trauma leading to cytokine release.
Primary Causes
Sustained pressure on the skin (e.g., sitting on a hard surface, wearing tight belts or shoulder straps, standing on ladders, carrying heavy bags, wearing tight footwear).
Sustained mechanical pressure causes local tissue deformation. This leads to delayed mast cell degranulation and the release of histamine. Crucially, the late response involves eosinophil and neutrophil infiltration, mediated by IL-6, TNF-alpha, and leukotrienes, which causes deep dermal and subcutaneous edema (angioedema-like). The deep inflammatory infiltrate is responsible for the characteristic pain rather than pruritus.
Diagnostic Criteria & Guidelines
Clinical history of delayed lesions following pressure. Confirmed by a standardized pressure test: application of a 2.5 to 4.5 kg weight via a 1.5 cm diameter cylinder to the thigh or back for 10-20 minutes, with the development of a palpable wheal 3 to 8 hours later.
Second-generation H1-antihistamines (e.g., Cetirizine 10 mg/day up to 40 mg/day off-label, or Fexofenadine up to 720 mg/day). However, antihistamines are often poorly effective for DPU. NSAIDs (e.g., Indomethacin 25-50 mg TID) can be used to manage pain but may exacerbate concurrent CSU.
Second-Line & Adjunctive Therapy
Leukotriene receptor antagonists (e.g., Montelukast 10 mg/day). Systemic corticosteroids (e.g., Prednisone 20-40 mg/day) for acute severe exacerbations (limited to short courses of 3-7 days). Omalizumab 300 mg subQ every 4 weeks is highly effective for refractory cases.
Surgical & Procedural Management
Not applicable.
Patient Counseling & Advice
Educate the patient about the delayed nature of the symptoms, which can make identifying triggers difficult. Explain that standard allergy pills (antihistamines) might not completely resolve the pain, and compliance with trigger avoidance is crucial.
Follow-Up & Monitoring Schedule
Review every 3-6 months to assess disease activity using the Urticaria Activity Score (UAS) modified for DPU, and monitor for side effects of systemic therapies.
Preventive Strategies
Strict avoidance of sustained pressure. Use of padding for mandatory pressure-bearing tasks.
Generally chronic. The average duration of the disease is 6 to 9 years, after which spontaneous remission can occur in about 50% of patients.